Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database

• Published in: Diagnostics (Basel) 2024-12, Vol.14 (24), p.2829
• Main Authors: Osei, Samuel Prince, Akomaning, Edwin, Florut, Teodora Francesca, Sodhi, Mohit, Lacy, Brian E, Aldhaleei, Wafa A, Bhagavathula, Akshaya Srikanth
• Format: Article
• Language: English
• Subjects: Abdomen; adverse drug reaction reporting systems; Algorithms; Constipation; Diabetes; diabetes mellitus; Diarrhea; FDA approval; Gastroesophageal reflux; gastrointestinal diseases; Glucagon; glucagon-like peptide-1 receptor; Hospitalization; Hypoglycemic agents; Intestinal obstruction; Medical errors; Medical research; Medicine, Experimental; Missing data; Nausea; Pain; Pancreatitis; Patient compliance; Patients; Pharmacovigilance; Software; Statistical analysis; Type 2 diabetes; Vomiting; Weight control; weight loss agents
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics14242829

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat obesity and diabetes but are linked to a variety of gastrointestinal (GI) adverse events (AEs). Real-world data on GLP-1 RA-related GI AEs and outcomes are limited. This study assessed GI AEs and adverse outcomes using the US FDA Adverse Event Reporting System (FAERS). This retrospective pharmacovigilance study used the US FDA FAERS database (2007-2023). We searched GLP-1 RA medications, AEs, and adverse outcomes. Demographic, treatment indication, and AE data were collected. Descriptive analysis involved frequencies and percentages, while reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multivariate logistic regression were used to analyze GLP-1 RA-related GI AEs and outcomes. From 2007 to 2023, a total of 187,757 AEs were reported with GLP-1 RAs, and 16,568 were GLP-1 RA-associated GI AEs in the US. Semaglutide was linked to higher odds of nausea (IC : 0.151, β : 0.314), vomiting (IC : 0.334, β : 0.495), and delayed gastric emptying (IC : 0.342, β : 0.453). Exenatide was associated with pancreatitis (IC : 0.601, β : 0.851) and death (ROR: 4.50, IC : 1.101). Overall, semaglutide had a broader range of notable adverse effects; by comparison, dulaglutide and liraglutide use was associated with fewer significant GI AEs. Analysis of the FAERS data reveals that GLP-1 RAs, particularly semaglutide and exenatide, are significantly associated with specific GI AEs, such as nausea, vomiting, delayed gastric emptying, and pancreatitis. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety. This study demonstrated the utility of pharmacovigilance data in identifying safety signals, which can inform future pharmacoepidemiological investigations to confirm causal relationships. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety.